About this raise
Koning, with a valuation of $230 million, is raising funds on StartEngine. The company has developed a revolutionary breast imaging technology that offers real isotropic 3D imaging. The Koning Breast CT creates high-contrast 3D breast images with high spatial resolution without the painful compression of mammograms. Koning has received approvals from FDA PMA, CFDA, CE Mark, and other global regulators and is designed for highly accurate early detection of breast cancer. Dr. Ruola Ning founded Koning in January 2002. The current crowdfunding campaign has a minimum target of $9,997.33 and a maximum target of $2,898,855.85. The campaign proceeds will be used for growth and expansion.
Investment Overview
Invested : $583,204
Deal Terms
Total Commitments
- Platform
- StartEngine
- Start Date
- 08/01/2022
- Close Date
- 12/30/2022
$9,997
$2,898,856
$489
Equity - Common
Growth Stage
RegCF
$5.69
$230,180,296
Company & Team
Company
- Year Founded
- 2002
- Industry
- Healthcare & Pharmaceuticals
- Tech Sector
- Distribution Model
- B2B
- Margin
- Medium
- Capital Intensity
- High
Financials
- Revenue +133% YoY
- $7,200,000
- Monthly Burn
- $405,789
-
Runway
- 1.3 months
- Gross Margin
- 57%
Upgrade to gain access
-
$12.50 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
Kingscrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Ratings 
Analyst Report
Koning's machines can reliably detect stage 0 and stage 1 cancers. Just how significant is this? Detecting breast cancer at stages 0 or 1 gives patients a 99% five-year survival rate. Its imaging technology can also detect small calcifications and small tumors in patients with small or dense breasts -- something current mammograms struggle with. Calcifications, by the way, are often an early indicator of breast disease.
This changes the game. Mammography has ruled the industry for 60 years. While flawed, it was -- for its time -- the best technology available. That's no longer the case.
Company Funding & Growth
Funding history
- Total Prior Capital Raised
- $2,101,141
- VC Backed?
- No
Growth Charts
Revenue History
Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.
Valuation History
Price per Share History
Note: Share prices shown in earlier rounds may not be indicative of any stock splits.